Diazeniumdiolate heterocyclic derivatives

US9108920B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Amjad Ali · Freehold, US
• Michael Man-Chu Lo · Rahway, US
• Robert K. Baker · Cranford, US
• Zhiqiang Guo · San Diego, US
• Brent Whitehead · Piscataway, US
• Timothy J. Henderson · Natick, US
• Edward Metzger · Edison, US
• Lin Yan · East Brunswick Township, US
• Shrenik K. Shah · Metuchen, US
• James Dellureficio · Millington, US
• Jun Wang · Nanjing, CN

Key dates

• Filing date: Oct 25, 2011
• Grant date: Aug 18, 2015
• Expiry date: Oct 25, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound having the structure: useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.